featured
Outcomes of Continued Ritlecitinib Treatment Through Week 48 in Patients With Alopecia Areata With or Without Early Target Responses
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of the American Academy of Dermatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trial
J Am Acad Dermatol 2024 Oct 17;[EPub Ahead of Print], M Piliang, C Lynde, B King, P Mirmirani, R Sinclair, M Senna, S Forman, L Bordone, P De La Cueva Dobao, R Wolk, SH Zwillich, H Tran, D Wajsbrot, HM Ahmed, L TakiyaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.